Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Acinetobacter baumannii Lung Infection in a Patient With Chronic Obstructive Pulmonary Disease

被引：80

作者：

Tan, Xin ^{[1
]}

Chen, Huaisheng ^{[2
]}

Zhang, Min ^{[3
,4
]}

Zhao, Ying ^{[5
]}

Jiang, Yichun ^{[2
]}

Liu, Xueyan ^{[2
]}

Huang, Wei ^{[3
,4
]}

Ma, Yingfei ^{[1
]}

机构：

[1] Chinese Acad Sci, Shenzhen Key Lab Synthet Genom, Guangdong Prov Key Lab Synthet Genom,Shenzhen Ins, CAS Key Lab Quantitat Engn Biol,Shenzhen Inst Syn, Shenzhen, Peoples R China

[2] South Univ Sci & Technol, Affiliated Hosp 1, Jinan Univ, Dept Crit Care Med,Shenzhen Peoples Hosp,Second C, Shenzhen, Peoples R China

[3] Shenzhen Peoples Hosp, Shenzhen Inst Resp Dis, Shenzhen, Peoples R China

[4] Southern Univ Sci & Technol, Affiliated Hosp 1, Jinan Univ,Shenzhen Peoples Hosp,Second Clin Med, Bacteriol & Antibacterial Resistance Surveillance, Shenzhen, Peoples R China

[5] Southern Univ Sci & Technol, Affiliated Hosp 1, Jinan Univ, Dept Geriatr,Shenzhen Peoples Hosp,Second Clin Co, Shenzhen, Peoples R China

来源：

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2021年 / 11卷

关键词：

carbapenem-resistant Acinetobacter baumannii; lung infection; personalized phage therapy; phage; endotoxin;

D O I：

10.3389/fcimb.2021.631585

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Overuse of antibiotics in clinical medicine has contributed to the global spread of multidrug-resistant bacterial pathogens, including Acinetobacter baumannii. We present a case of an 88-year-old Chinese man who developed hospital-acquired pneumonia caused by carbapenem-resistant A. baumannii (CRAB). A personalized lytic pathogen-specific single-phage preparation was nebulized to the patient continuously for 16 days in combination with tigecycline and polymyxin E. The treatment was well tolerated and resulted in clearance of the pathogen and clinical improvement of the patient's lung function.

引用

页数：7

共 50 条

[21] In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates
Singkham-in, Uthaibhorn
Chatsuwan, Tanittha
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 91 (02) : 169 - 174
[22] Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model
Avery, Lindsay M.
Abdelraouf, Kamilia
Nicolau, David P.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (11)
[23] Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study
Russo, Alessandro
Bassetti, Matteo
Ceccarelli, Giancarlo
Carannante, Novella
Losito, Angela Raffaella
Bartoletti, Michele
Corcione, Silvia
Granata, Guido
Santoro, Antonella
Giacobbe, Daniele Roberto
Peghin, Maddalena
Vena, Antonio
Amadori, Francesco
Segala, Francesco Vladimiro
Giannella, Maddalena
Di Caprio, Giovanni
Menichetti, Francesco
Del Bono, Valerio
Mussini, Cristina
Petrosillo, Nicola
De Rosa, Francesco Giuseppe
Viale, Pierluigi
Tumbarello, Mario
Tascini, Carlo
Viscoli, Claudio
Venditti, Mario
JOURNAL OF INFECTION, 2019, 79 (02) : 130 - 138
[24] Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii:: patient prognosis and risk-factors for colonisation and infection
Tomas, MD
Cartelle, M
Pertega, S
Beceiro, A
Llinares, P
Canle, D
Molina, F
Villanueva, R
Cisneros, JM
Bou, G
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (07) : 540 - 546
[25] Characterisation and sequencing of the novel phage Abp95, which is effective against multi-genotypes of carbapenem-resistant Acinetobacter baumannii
Li Huang
Siyi Huang
Lingli Jiang
Jingjie Tan
Xueping Yan
Chunmei Gou
Xinchong Chen
Lijuan Xiang
Dali Wang
Guangtao Huang
Yixin Zhang
Chengliang Deng
Scientific Reports, 13 (1)
[26] Characterisation and sequencing of the novel phage Abp95, which is effective against multi-genotypes of carbapenem-resistant Acinetobacter baumannii
Huang, Li
Huang, Siyi
Jiang, Lingli
Tan, Jingjie
Yan, Xueping
Gou, Chunmei
Chen, Xinchong
Xiang, Lijuan
Wang, Dali
Huang, Guangtao
Zhang, Yixin
Deng, Chengliang
SCIENTIFIC REPORTS, 2023, 13 (01):
[27] Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii : A multi-centre clinical experience
Russo, Alessandro
Gulli, Sara Palma
D'Avino, Alessandro
Borrazzo, Cristian
Carannante, Novella
Dezza, Francesco Cogliati
Covino, Sara
Polistina, Giorgio
Fiorentino, Giuseppe
Trecarichi, Enrico Maria
Mastroianni, Claudio Maria
Torti, Carlo
Oliva, Alessandra
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 64 (01)
[28] In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates
Muderris, Tuba
Manyasli, Gulden Dursun
Sezak, Nurbanu
Kaya, Selcuk
Demirdal, Tuna
Yurtsever, Suereyya Gul
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2024, 29 (01) : 331
[29] Polyvinylpyrrolidone-capped silver nanoparticle inhibits infection of carbapenem-resistant strain of Acinetobacter baumannii in the human Pulmonary epithelial cell
Tiwari, Vishvanath
Tiwari, Monalisa
Solanki, Vandana
FRONTIERS IN IMMUNOLOGY, 2017, 8
[30] Preoptimized phage cocktail for use in aerosols against nosocomial transmission of carbapenem-resistant Acinetobacter baumannii: A 3-year prospective intervention study
Chen, Li-Kuang
Chang, Jui-Chih
Chu, Hsiu-Tzu
Chen, Yi-Ting
Jiang, Hui-Li
Wang, Lih-Shinn
Teh, Soon-Hian
Yang, Hui-Hua
Chen, Dar-Sen
Li, Yu-Zhong
Chang, Chin-Cheng
Sankhla, Debangana
Tseng, Chun-Chieh
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2022, 236

← 1 2 3 4 5 →